Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIMET metformin after myocardial infarction in newly detected prediabetes
2019-001487-30Phase 3Terminated
- Sponsor
- Karolinska Institutet
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of metformin in prediabetes and myocardial infarction (MI) (2 arms), sponsored by Karolinska Institutet. Primary endpoint: Time to major cardiovascular event. Started Dec 2019; status: terminated.
02
Drugs
metformin
03
Conditions
prediabetesmyocardial infarction (MI)
Beyond the preview
Go deeper on 2019-001487-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001487-30.